Ribavirin was demonstrated to have an antiviral effect on respiratory syncytial virus in vitro. A 50% reduction in plaque number was observed at concentrations of 3 to 10 Ag of ribavirin per ml. This effect was observed when the drug was added as late as 12 h postinfection. At concentrations of greater than 10 ,ug of ribavirin per ml, the size of the syncytial plaque also noticeably decreased. Ribavirin similarly decreased the number of infectious units released into the culture supernatant. The antiviral effect was observed to be inversely related to the size of the viral inoculum, although all concentrations above 3.2 jig of ribavirin per ml visibly lessened the cytopathic effect regardless of the inoculum. Cloning of respiratory synctial virus in inhibitory concentrations of ribavirin failed to show increased resistance to the drug.
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Ribavirin (1-f8-D-ribofuranosyl-1,2,4-triazole-3-carboxamide) is a synthetic nucleQside that has antiviral properties against a large number of both ribonucleic acid and deoxyribonucleic acid viruses in vitro (5, 14, 20) . In experimental influenza infections in mice, ribavirin has reduced mortality and increased survival time when administered by the oral (4, 6), intraperitoneal (6, 17, 18) , and aerosol routes (17) . In one study of experimental influenza infections in humans, ribavirin was shown to ameliorate symptoms and fever (8) , although other investigators reported that lower doses had only marginal effectiveness against influenza (2, 19) .
The purpose of this study was to assess the in vitro susceptibility of respiratory syncytial virus (RSV) to ribavirin. Respiratory syncytial virus is a major cause of pneumomia, bronchiolitis, and other respiratory diseases in infants, young children, and even adults (6, 16 ). An inactivated RSV vaccine failed to decrease the incidence of infection and was associated with the paradoxical development of more severe disease when natural infection occurred (7) . In addition, attempts to develop a vaccine with live, attenuated, temperature-sensitive mutants have not been successful (10 Table  3 . Although these isolates were slightly less susceptible than was the Long strain of RSV, the results are comparable.
Ribavirin reduced not only the number of plaque-forming units but also the size of the syncytia (Tables 1 and 3 ). In the presence of 10 ,ug of ribavirin per ml, syncytial plaques developed which were one-quarter the size of those obtained without ribavirin. The small-plaque morphology was observed for all RSV strains (both Long strain and wild-type strains) grown in the presence of concentrations of ribavirin of 10 ,ug/ml or higher. When ribavirin concentrations above 10 ,Lg/ml were examined (16 and 20 ,ug/ml), it appeared that the plaques became even smaller in all strains examined. At 32 ,ug/ ml, no plaques could be seen.
Effect of time of addition of ribavirin. Ribavirin was added before or at various times after initiation of infection. After 12 h, the liquid medium with ribavirin was removed, and the wells were covered with an agarose overlay containing ribavirin. Ribavirin reduced plaque formation by 50% at a concentration of less than 3.2 ,ug/ml when added early in relation to initiation of infection (-2, 0, and 1 h), whereas 3.2 to 10 ,ug/ml was needed when added later (2, 8 , and 12 h). However, a 95% plaque reduction was achieved at a ribavirin concentration of 10 ug/ ml, even if the drug was added as late as 12 h after inoculation of the virus.
Inhibition of viral release by ribavi'rn.
The titer of virus in the supernatants of cells infected with RSV at a multiplicity of infection (MOI) of 2 was studied on sequential days to determine the inhibitory effect of ribavirin on viral release. In addition to the supernatant samples, the cell sheet was also trypsinized, counted, and assayed. The results of this experiment are shown in Table 4 . At ribavirin concentrations of 10 ,ig/ml or higher, more than a 100-fold reduc- Simultaneous titration of the three generations of the Long strain of RSV cloned in the presence of ribavirin failed to show any increased resistance to ribavirin (Table 6 ). One clone from each generation was assayed in duplicate by plaque assay in the presence ofseveral concentrations of ribavirin. Despite the selection of these two clones from cultures grown in the presence of 10 and then 15 jig of drug (second cloning) per ml, there was no significant difference in their susceptibility to ribavirin after two clonings as assessed by the Student t test (P > 0.1).
DISCUSSION
Our data demonstrate in vitro susceptibility of RSV to ribavirin at levels very similar to those required to inhibit influenza A and B viruses (2, (15) . RSV plaque size also was markedly reduced at concentrations of ribavirin as low as 10 ,ug/ml; at this dose, the plaques were at most onequarter the area of controls. At increasing levels of the drug, these plaques became progressively smaller. Similarly, Oxford (9) has reported that the plaque size of fowl plaque virus was significantly smaller in the presence of ribavirin at a concentration of 0.1 ,lM (24.4 ,ug/ml), the lowest dose tested. Ribavirin has been shown previously to inhibit the synthesis of influenza viral antigens and infectious virus in the early stage of viral replication at 3 to 4 h after infection (3). Addition of ribavirin at 5 h had no beneficial effect in their in vitro system. By contrast, inhibition of RSV plaque formation in our study occurred at approximately the same ribavirin concentration even if addition of the drug was delayed up to 12 h after infection. The difference between their results and ours may be due to the slower replication cycle of RSV as compared with influenza virus. The last time tested in our study, 12 h, was chosen because it is the reported end of the viral eclipse period. Time periods longer than 12 h might have allowed cell-to-cell spread of virus via the liquid supematant and interfered with the determination of the 50% endpoint.
Durr and Lindh, whose influenza model is discussed above (3), used an MOI of 0.1 and measured the effect of only one concentration of ribavirin (25 ,tg/ml) added at various times after infection. In our RSV in vitro system, susceptibility to ribavirin was most evident at low MOIs. Even concentrations of ribavirin as high as 32. 5 ,tg/ml could not suppress the formation of CPE if the MOI was 1.0. Thus, the difference in methodology also may explain the observed difference in results. The RSV experiments were done with serial dilutions of virus stock, and the plaque assay was counted at wells with about 100 plaques per plate (MOI = 0.001). Although ribavirin appears to have an inhibitory effect on CPE at concentrations above 3.2 ,u/ml regardless of the inoculum size, it rarely completely suppressed the formation of syncytia except at high levels of the drug. Even at high MOIs, the quantity of virus released from cells and the amount of cell-associated virus (the trypsinized infected HEp-2 cell sheets are probably a reflection of the number of infectious centers) are markedly reduced despite the visible presence of CPE. Thus, ribavirin has been shown to affect a reduction in several parameters of RSV reproduction: plaque number, plaque size, titer ofreleased virus, and intracellular virus production.
The applicability of these results to the treatment of human infections due to RSV is not straightforward. In our experiments we used a constant concentration of ribavirin maintained over the length of the experiment. In humans, the serum concentration of the drug never attains the level needed for a 50% plaque reduction; ribavirin only reaches a serum concentration of 0.22 jig/ml, 1 to 2 h after a 400-mg oral dose (13). However, this subtherapeutic level may have little relevance since more than 70% of the drug is found in tissues 1 h after a dose. In fact, in rats, the concentration of ribavirin and its metabolites in the lung is five to seven times the serum concentration. This tissue affinity may explain the improved survival of mice with influenza treated with parenteral ribavirin (16 mg/kg). Similarly, clinical trials of only 1,000 ,ug of ribavirin per day have ameliorated symptoms in experimental human influenza infections (8) . Although one would have expected the serum levels of ribavirin in these volunteers to be lower than those levels needed to inhibit the virus, nonetheless, an effect was seen.
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on December 22, 2017 by guest http://aac.asm.org/ Downloaded from tions in animals and humans suggest that the susceptibility of RSV to ribavirin may be at a clinically attainable level and that evaluation of ribavirin in an animal model such as the cotton rat (Sigmodon hispides) (11) or ferret may be warranted.
